Belite Bio (NASDAQ:BLTE) CEO Yu-Hsin Lin Sells 26,000 Shares of Stock

Posted by George Bondi on Sep 9th, 2026

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) CEO Yu-Hsin Lin sold 26,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $196.56, for a total transaction of $5,110,560.00. Following the sale, the chief executive officer owned 70,134 shares of the company’s stock, valued at approximately $13,785,539.04. The trade was a 27.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Yu-Hsin Lin also recently made the following trade(s):

On Friday, September 4th, Yu-Hsin Lin sold 74,435 shares of Belite Bio stock. The stock was sold at an average price of $187.71, for a total value of $13,972,193.85.
On Wednesday, August 12th, Yu-Hsin Lin sold 365 shares of Belite Bio stock. The stock was sold at an average price of $180.35, for a total value of $65,827.75.

Belite Bio Price Performance

Shares of BLTE traded down $9.69 during trading hours on Wednesday, hitting $183.16. The company’s stock had a trading volume of 214,121 shares, compared to its average volume of 214,515. The business has a 50 day simple moving average of $160.55 and a two-hundred day simple moving average of $158.72. The company has a market cap of $7.38 billion, a price-to-earnings ratio of -67.09 and a beta of -1.23. Belite Bio, Inc. Sponsored ADR has a 52-week low of $64.80 and a 52-week high of $200.00.

Belite Bio (NASDAQ:BLTE – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.54) EPS for the quarter. Research analysts predict that Belite Bio, Inc. Sponsored ADR will post -3.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BLTE. Cantor Fitzgerald increased their target price on Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Canaccord Genuity Group assumed coverage on shares of Belite Bio in a research report on Friday, September 4th. They set a “buy” rating and a $303.00 price target for the company. HC Wainwright set a $245.00 price target on Belite Bio in a report on Tuesday. Jefferies Financial Group reissued a “hold” rating on shares of Belite Bio in a research note on Wednesday. Finally, Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research report on Friday, August 14th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Belite Bio presently has an average rating of “Moderate Buy” and a consensus price target of $218.73.

Read Our Latest Research Report on BLTE

Institutional Trading of Belite Bio

A number of hedge funds and other institutional investors have recently modified their holdings of BLTE. Darwin Global Management Ltd. bought a new stake in Belite Bio during the fourth quarter worth about $486,915,000. RA Capital Management L.P. purchased a new position in shares of Belite Bio during the third quarter valued at approximately $64,750,000. RTW Investments LP lifted its holdings in shares of Belite Bio by 128.9% during the fourth quarter. RTW Investments LP now owns 715,332 shares of the company’s stock valued at $114,425,000 after purchasing an additional 402,832 shares during the last quarter. Millennium Management LLC increased its position in Belite Bio by 2,594.6% during the 4th quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock valued at $89,399,000 after buying an additional 538,141 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its holdings in Belite Bio by 732.0% in the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock worth $66,262,000 after acquiring an additional 364,451 shares in the last quarter. 0.53% of the stock is owned by hedge funds and other institutional investors.

About Belite Bio

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.